PriceTargets.com logo

ABIVAX Société Anonyme - ABVX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.67
  • Forecasted Upside: 386.99%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$7.94 As of 12/17/2024 01:00 AM ET
▲ +0.04 (0.51%)

This chart shows the closing price for ABVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ABIVAX Société Anonyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABVX

Analyst Price Target is $38.67
▲ +386.99% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for ABIVAX Société Anonyme in the last 3 months. The average price target is $38.67, with a high forecast of $50.00 and a low forecast of $16.00. The average price target represents a 386.99% upside from the last price of $7.94.

This chart shows the closing price for ABVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in ABIVAX Société Anonyme. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2024Citizens JmpUpgradeStrong-Buy
12/4/2024JMP SecuritiesInitiated CoverageOutperform$33.00
7/29/2024LaidlawInitiated CoverageBuy$48.00
5/20/2024BTIG ResearchInitiated CoverageBuy$43.00
4/29/2024Piper SandlerInitiated CoverageOverweight$42.00
4/29/2024GuggenheimInitiated CoverageBuy$50.00
4/11/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$15.00 ➝ $16.00
11/14/2023Leerink PartnrsReiterated RatingOutperform
11/14/2023Morgan StanleyInitiated CoverageEqual Weight$15.00
11/14/2023Leerink PartnersInitiated CoverageOutperform$20.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ABIVAX Société Anonyme logo
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Read More

Today's Range

Now: $7.94
Low: $7.66
High: $8.09

50 Day Range

MA: $9.40
Low: $7.11
High: $10.69

52 Week Range

Now: $7.94
Low: $7.11
High: $17.02

Volume

124,924 shs

Average Volume

95,338 shs

Market Capitalization

$502.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of ABIVAX Société Anonyme?

The following sell-side analysts have issued stock ratings on ABIVAX Société Anonyme in the last year: BTIG Research, Citizens Jmp, Guggenheim, JMP Securities, Laidlaw, Morgan Stanley, and Piper Sandler.
View the latest analyst ratings for ABVX.

What is the current price target for ABIVAX Société Anonyme?

0 Wall Street analysts have set twelve-month price targets for ABIVAX Société Anonyme in the last year. Their average twelve-month price target is $38.67, suggesting a possible upside of 387.0%. Guggenheim has the highest price target set, predicting ABVX will reach $50.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $16.00 for ABIVAX Société Anonyme in the next year.
View the latest price targets for ABVX.

What is the current consensus analyst rating for ABIVAX Société Anonyme?

ABIVAX Société Anonyme currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABVX will outperform the market and that investors should add to their positions of ABIVAX Société Anonyme.
View the latest ratings for ABVX.

What other companies compete with ABIVAX Société Anonyme?

Other companies that are similar to ABIVAX Société Anonyme include Amphastar Pharmaceuticals, Disc Medicine, Tarsus Pharmaceuticals, CG Oncology and Harmony Biosciences. Learn More about companies similar to ABIVAX Société Anonyme.

How do I contact ABIVAX Société Anonyme's investor relations team?

The company's listed phone number is 33-1-53-83-09-63 and its investor relations email address is [email protected]. The official website for ABIVAX Société Anonyme is www.abivax.com. Learn More about contacing ABIVAX Société Anonyme investor relations.